First AD

Second AD

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

Video content above is prompted by the following question:

In which patients might you consider first-line doublet therapy (venetoclax + BTK inhibitor)?

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes

UCI Health Chao Family Comprehensive Cancer Center

Cancer Centers

Partner

Weill Cornell Medical College Sandra & Edward Meyer Cancer Center

Patient with Newly Diagnosed CLL with High-Risk Features

Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL

Navigating Continuous BTKi Therapy for CLL in the 1L Setting

Implications of Real-World Data in the 1L Treatment of High-Risk CLL

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

Perspectives on Shared Decision-Making in the Treatment of CLL

Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

Expert Insights for Long-Term Treatment Planning in CLL

Patient with R/R CLL Treated with 2L Venetoclax Therapy

Navigating 2L Treatment Options in CLL

Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications

Management Strategies for BTKi-Related CVAEs in CLL

Updates in CLL Treatment Strategies with Noncovalent BTKis

Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL